- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01188915
Personalised Program for Women Treated for Hodgkin Disease (PROPER)
Personalised Program for Women Treated for Hodgkin Disease : Risk Evaluation of Breast Cancer and Intensive Screening Program for Women at High Risk of Breast Cancer. PROPER/IPC 2010-001
After treatment for Hodgkin disease, secondary cancer, in particular breast cancer induced by treatment, are the first cause of death.
The investigators will estimate the risk to develop breast cancer in this population of women treated for hodgkin disease, and will propose women at high rish to participate in an intensive screening program based on an annual detection based on mammography, echography, and RMI.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Marseille, Frankrig, 13009
- François EISINGER, PhD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- women > 18 years
- treated for Hodgkin disease
- signed informed consent
- high risk of breast cancer
Exclusion Criteria:
- patients unable to have a regular follow-up
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: intensive screening
annual breast cancer detection based on mammography, echography and RMI.
|
Each year, women will have breast cancer detection based on mammography, echography and RMI.
Questionaries will also be completed.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
efficacy of the screening
Tidsramme: 15 years
|
The efficacy of the screening will be evaluated by the rate of early stage breast cancer detected.
The rate of in situ, < 10 mm(T1b), and N0 will be estimated.
|
15 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
interest
Tidsramme: 1 month
|
The rate of interest is the % of women at high risk who will accept the intensive screening
|
1 month
|
|
adhesion
Tidsramme: 1 month
|
The adhesion rate is the % of women who will effectively undergo the first screnning among the women who had accepted their participation in this intensive screening
|
1 month
|
|
compliance
Tidsramme: 15 years
|
The compliance will be evaluated yearly.
The number of exam realised compared to the theoric number and the time between 2 exams will be estimated.
|
15 years
|
|
psychologic impact
Tidsramme: 15 years
|
The psychologic impact will be assessed yearly by questionnaries evaluating quality of life, anxiety and satisfaction.
|
15 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: François EISINGER, PhD, Institut Paoli-Calmettes
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- PROPER/IPC 2010-001
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .